PALI
Palisade Bio, Inc.
PALI
Palisade Bio, Inc.
Palisade Bio, Inc. (PALI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Management to participate in investor meetings on July 14-15 in Boston Denver, CO, July 10, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage b
Palisade Bio offers a speculative early-stage opportunity, advancing PALI-2108, a gut-restricted PDE4 inhibitor for UC and Crohn's disease. PALI-2108's Phase 1 trials showed favorable safety, target e